HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kay, R. Search for Related Content PubMed Articles by Kay, R.

Anticoagulation for Acute Ischaemic Stroke?

Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China. E-mail: lichikay{at}cuhk.ed.hk

EXTRACT

INTRODUCTION

Six years ago, in December 1955, there appeared in the New England Journal of Medicine an article that revolutionized the way we think of stroke. I am referring, of course, to the NINDS paper ‘Tissue plasminogen activator for acute ischemic stroke’ (The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group 1995), which singularly made the FDA recognize rt-PA as still the only approved treatment for stroke. Trailing behind that landmark paper was our paper from Hong Kong, ‘Low-molecular-weight heparin for the treatment of acute ischemic stroke’ (Kay et al. 1995), which showed that an anticoagulant, nadroparin, if given subcutaneously within 48 h of stroke onset could also reduce death or disability. This paper temporarily raised the hope that there might be another treatment for stroke than thrombolysis within three hours. But as more anticoagulant trials were completed and published, that hope has evaporated. In this article ...

[PDF of this article]